{"id":3634,"date":"2026-10-06T09:00:00","date_gmt":"2026-10-06T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3634"},"modified":"2026-10-06T09:00:00","modified_gmt":"2026-10-06T13:00:00","slug":"furvent-misses-its-central-review-endpoint","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3634","title":{"rendered":"FURVENT Misses Its Central Review Endpoint"},"content":{"rendered":"

Company<\/strong><\/p>\n

ArriVent BioPharma; Shanghai Allist Pharmaceuticals<\/p>\n

Event Type<\/strong><\/p>\n

Phase 3 topline result (primary endpoint missed)<\/p>\n

Modality<\/strong><\/p>\n

Small molecule (oral EGFR tyrosine-kinase inhibitor)<\/p>\n

Asset<\/strong><\/p>\n

Firmonertinib<\/p>\n

Target<\/strong><\/p>\n

EGFR exon 20 insertion mutations<\/p>\n

Disease Area<\/strong><\/p>\n

EGFR exon 20 insertion non-small-cell lung cancer (first line)<\/p>\n

Summary<\/h4>\n

ArriVent and its Chinese development partner Allist reported that first-line firmonertinib monotherapy did not meet the blinded independent central review progression-free-survival endpoint in the global Phase 3 FURVENT study of EGFR exon 20 insertion non-small-cell lung cancer. The higher dose improved the numerical response rate, but its primary PFS comparison was not statistically significant. The result narrows the evidence for this particular global first-line strategy; it does not adjudicate other mutation classes or lines of therapy.<\/p>\n

The randomized three-arm study enrolled 398 patients in the United States, Europe, Japan and China. Firmonertinib 240 mg once daily yielded 11.0 months median central-review PFS versus 9.5 months with platinum plus pemetrexed: hazard ratio 0.75 (95% CI 0.55\u20131.02), p=0.0654. The 160 mg dose yielded 8.4 months and hazard ratio 0.91 (0.67\u20131.25). Confirmed central-review response rates were 60%, 35% and 33%, respectively.<\/p>\n

Investigator-assessed PFS favored 240 mg more strongly (11.1 versus 7.1 months; hazard ratio 0.61), but it was a secondary endpoint and disagrees with the prespecified central review. Grade 3 or higher treatment-emergent adverse events occurred in 52%, 53% and 55%; treatment-related grade 3 or higher events in 26%, 22% and 40%. Overall survival is immature; the company described only a trend.<\/p>\n

Deep Analysis<\/h4>\n

The dose-response in central-review response rate and the 240 mg hazard ratio support antitumor activity, but response is insufficient to rescue a missed primary endpoint. Divergence between local and central PFS assessments may reflect scan timing, ascertainment, censoring or measurement variability; patient-level data are needed to diagnose it. The 240 mg confidence interval includes no benefit and the p value is above the stated conventional threshold. Median differences alone are an incomplete effect measure. Subtype-level exon 20 insertion data, intracranial outcomes, exposure and discontinuation rates are unavailable in the release.<\/p>\n

The competitive implication is constrained to first-line monotherapy against platinum-pemetrexed in the studied population. Firmonertinib is approved in China for classic EGFR mutations and for exon 20 insertion disease after platinum or when platinum is intolerable. Those distinct indications cannot validate first-line exon 20 efficacy globally. FURVENT may make a straightforward first-line monotherapy filing harder, although the complete dataset and regulator discussion are still pending. The separate PACC-mutant ALPACCA trial tests another molecular subgroup.<\/p>\n

Interpretation A is that 240 mg has real activity but the selected comparator, heterogeneity or central assessment reduced the observed PFS contrast; the 60% response rate and hazard ratio below one support it, while the confidence interval and endpoint miss limit it. Interpretation B is that response depth does not translate into durable disease control; the 1.5-month median difference and 160 mg result support caution, while the immature survival and absent duration-of-response data prevent a definitive efficacy conclusion. Mature survival, CNS and insertion-subtype analyses could upgrade or falsify either view.<\/p>\n

Company and Product Background<\/h4>\n

Firmonertinib is an oral EGFR tyrosine-kinase inhibitor originally developed by Shanghai Allist Pharmaceuticals and partnered with ArriVent for global development. EGFR exon 20 insertions alter kinase structure and confer a different treatment challenge from common EGFR exon 19 deletion and L858R mutations. The drug is also being studied in EGFR PACC-mutant lung cancer. FURVENT compared two oral doses with first-line platinum-pemetrexed chemotherapy.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • New clinical data on 6 October 2026: prespecified central-review PFS endpoint missed.<\/li>\n
  • 240 mg central-review PFS: 11.0 versus 9.5 months; HR 0.75, p=0.0654.<\/li>\n
  • Central-review response: 60% versus 33%, a signal requiring duration and survival context.<\/li>\n
  • China approval is in different biomarker or treatment-line settings.<\/li>\n
  • Next evidence: complete FURVENT dataset, mature OS, CNS outcomes and regulatory feedback.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    FURVENT is a negative registrational result for the tested first-line strategy, despite evidence of tumor shrinkage at 240 mg. The most consequential unanswered question is why objective response and investigator-assessed PFS diverged from the central PFS result. A future path should be judged on full patient-level durability and survival data, not on the response rate alone.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 5 of 5. Signal Direction: negative for the tested FURVENT primary endpoint; uncertain for other settings. Confidence in Facts: high for the company-reported aggregate trial numbers and registry design. Confidence in Interpretation: moderate. Missing facts: full statistical analysis plan, insertion-subtype balance, censoring, duration of response, intracranial efficacy, discontinuation and mature overall survival. Red-team: neither the favorable secondary results nor the China approvals overturn the missed prespecified endpoint.<\/p>\n","protected":false},"excerpt":{"rendered":"

    ArriVent and its Chinese development partner Allist reported that first-line firmonertinib monotherapy did not meet the blinded independent central review progression-free-survival endpoint in the global Phase 3 FURVENT study of EGFR exon 20 insertion…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[938,937,940,939,941,18],"class_list":["post-3634","post","type-post","status-publish","format-standard","hentry","category-therapeutic-indication","tag-allist","tag-arrivent-biopharma","tag-egfr-exon-20-insertion","tag-firmonertinib","tag-furvent","tag-non-small-cell-lung-cancer"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3634"}],"version-history":[{"count":0,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3634\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}